Background: While the amount of information on many issues related to COVID-19 has increased, the long-term consequences of illness and disability remain largely unclear. In previous studies on COVID-19 infections, long-lasting functional and symptomatic abnormalities have also been shown. It is predicted that survivors of COVID-19 may have to deal with physical or psychological problems later.
View Article and Find Full Text PDFNon-small cell lung cancer (NSCLC) is characterized by diagnosis at an advanced stage, low rate of operability and poor survival. Therefore, there is a need for a biomarker in NSCLC patients to predict the likely outcome and to accurately stratify the patients in terms of the most appropriate treatment modality. To evaluate prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in NSCLC.
View Article and Find Full Text PDFPurpose: GOLD 2019 proposed a novel treatment decision tool for follow-up based on the predominant trait (exacerbation or dyspnea) of patients, alongside treatment escalation and de-escalation strategies. This study was designed to provide an up-to-date snapshot of patient and disease characteristics, treatment pathways, and healthcare resource use (HRU) in COPD in real life, and comprehensively examine patients considering GOLD 2019 recommendations.
Patients And Methods: This mixed design, observational, multicenter (14 pulmonology clinics) study included all patients with a documented COPD diagnosis (excluding asthma-COPD overlap [ACO]) for ≥12 months, aged ≥40 years at diagnosis who had a COPD-related hospital visit, spirometry test and blood eosinophil count (BEC) measurement under stable conditions within the 12 months before enrollment between February and December 2020.
Spontaneous hydropneumothorax (HP) and mediastinal emphysema (ME) are infrequently presented complications of pulmonary tuberculosis (TB). A-34-year-old Pakistani male presented with dyspnea, productive cough, and right-sided pleuritic chest pain. He had no history of any surgery, TB, comorbid disease, or other serious pulmonary diseases.
View Article and Find Full Text PDFBackground: According to the World Health Organisation reports (WHO), COPD is the third leading cause of overall in the World by 2020.
Aim: We aimed to determine the prognostic predictors of 90-day mortality after an initial exacerbation in patients with acute exacerbation of COPD (AECOPD).
Results: Increased Charlson Comorbidity Score(CCS) (HR:1.
Background: Sleep architecture and sleep hygiene might be disrupted by several pathogenetic mechanisms, and the effect of smoking has not been evaluated.
Objective: To investigate the effect of smoking on sleep hygiene behaviors that might be associated with the deterioration of quality-of-life (QoL) parameters.
Methods: In a prospective cross-sectional study, smokers (n=114) and nonsmokers (n=119) were included.
Introduction: Deterioration in sleep quality and sleep hygiene may result in impairments on mental and physical health leading to deterioration of quality of life (QoL) in healthcare shift workers. We aimed to determine the presence of sleep deterioration as well as poor sleep hygiene, and if any, the effects of these on health-related outcomes.
Methods: This study prospectively included healthcare professionals who did and did not work shifts (n=90 and n=66, respectively).
Objectives: The exact role of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila in the development of chronic obstructive pulmonary disease exacerbations remains to be elucidated. This study was conducted to identify nonspecific and atypical pathogens associated with acute exacerbations of COPD.
Materials And Methods: Between February 2013 and February 2015, 107 patients were analyzed.
The bronchodilator efficacy of a once-daily fixed-dose combination of tiotropium/formoterol (18/12 µg administered via a dry-powder inhaler, Discair) [TIO/FORM group] vs a single-dose of tiotropium (18 µg) by Handihaler alone [TIO group], or combined with formoterol 12 µg twice-daily by Aerolizer [TIO/FORM group] was compared in patients with moderate-to-severe stable COPD. COPD patients were randomized (28 patients/group) to receive TIO/FORM, TIO or TIO/FORM. AUC for the changes in FEV and FVC over a 24-h period; bronchodilator response (100 ml improvement in FEV) in the first 30 min; maximum changes in FEV and FVC; and safety data were recorded.
View Article and Find Full Text PDF